A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To date no comparative trials have been done, to our knowledge, of fixed-dose artemisinin combination therapies (ACTs) for the treatment of Plasmodium falciparum malaria in pregnancy. Evidence on the safety and efficacy of ACTs in pregnancy is needed as these drugs are being used increasingly throughout the malaria-affected world. The objective of this study was to compare the efficacy, tolerability, and safety of artemether-lumefantrine, the most widely used fixed ACT, with 7 d artesunate monotherapy in the second and third trimesters of pregnancy. METHODS AND FINDINGS: An open-label randomised controlled trial comparing directly observed treatment with artemether-lumefantrine 3 d (AL) or artesunate monotherapy 7 d (AS7) was conducted in Karen women in the border area of northwestern Thailand who had uncomplicated P. falciparum malaria in the second and third trimesters of pregnancy. The primary endpoint was efficacy defined as the P. falciparum PCR-adjusted cure rates assessed at delivery or by day 42 if this occurred later than delivery, as estimated by Kaplan-Meier survival analysis. Infants were assessed at birth and followed until 1 y of life. Blood sampling was performed to characterise the pharmacokinetics of lumefantrine in pregnancy. Both regimens were very well tolerated. The cure rates (95% confidence interval) for the intention to treat (ITT) population were: AS7 89.2% (82.3%-96.1%) and AL 82.0% (74.8%-89.3%), p = 0.054 (ITT); and AS7 89.7% (82.6%-96.8%) and AL 81.2% (73.6%-88.8%), p = 0.031 (per-protocol population). One-third of the PCR-confirmed recrudescent cases occurred after 42 d of follow-up. Birth outcomes and infant (up to age 1 y) outcomes did not differ significantly between the two groups. The pharmacokinetic study indicated that low concentrations of artemether and lumefantrine were the main contributors to the poor efficacy of AL. CONCLUSION: The current standard six-dose artemether-lumefantrine regimen was well tolerated and safe in pregnant Karen women with uncomplicated falciparum malaria, but efficacy was inferior to 7 d artesunate monotherapy and was unsatisfactory for general deployment in this geographic area. Reduced efficacy probably results from low drug concentrations in later pregnancy. A longer or more frequent AL dose regimen may be needed to treat pregnant women effectively and should now be evaluated. Parasitological endpoints in clinical trials of any antimalarial drug treatment in pregnancy should be extended to delivery or day 42 if it comes later. TRIAL REGISTRATION: Current Controlled Trials ISRCTN86353884.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of artesunate in early pregnancy has not led to any additional toxic effects [135, 136].”
From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in Thailand the cure rate at day 42 was only 82%,138 possibly due to the low day 7 lumefantrine concentrations.”
From Malaria in pregnancy. (2013) · cites this paper as [138]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“AL was safe and well tolerated.136–138”
From Malaria in pregnancy. (2013) · cites this paper as [138]
In the citing paper
“However, application of highly sensitive molecular techniques confirmed that the frequency of low level (submicroscopic) infections is higher than expected in all endemic regions [16,17].”
From Submicroscopic infection of placenta by Plasmodium produces Th1/Th2 cytokine imbalance, inflammation and hypoxia in women from north-west Colombia (2014) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical assessment of gestational age in the newborn infant
Dubowitz, L. M. S., Dubowitz, V., & Goldberg, C. (1970) · The Journal of Pediatrics · doi:10.1016/s0022-3476(70)80038-5 · Cited by 2,241
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Price, R. N., Uhlemann, A.-C., Brockman, A., McGready, R., Ashley, E., Phaipun, L., Patel, R., Laing, K., Looareesuwan, S., White, N. J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16767-6 · Cited by 853 · cited 1×
“Resistance is associated with an increase in Pfmdr1 copy numbers [33–35].”
BackgroundSelf-citationClinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine
White, N. J., van Vugt, M., & Ezzet, F. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937020-00002 · Cited by 351
Self-citationPrice, R. N., Uhlemann, A.-C., van Vugt, M., Brockman, A., Hutagalung, R., Nair, S., Nash, D., Singhasivanon, P., Anderson, T. J. C., Krishna, S., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503423 · Cited by 317 · cited 1×
“Parasites with increased Pfmdr1 copy number are also slightly less sensitive to artemisinin derivatives, although the differences are much less than for lumefantrine [36].”
BackgroundSelf-citationMalaria during pregnancy in an area of unstable endemicity.
Nosten, F., ter Kuile, F., Maelankirri, L., Decludt, B., & White, N. J. (1991) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(91)90205-d · Cited by 294 · cited 1×
“The ANCs provided early detection and treatment of malaria and reduced both morbidity and mortality [3].”
BackgroundSelf-citationEyes on the present and looking into the future
Piva, J. P., & Garcia, P. C. R. (2001) · Jornal de Pediatria · doi:10.2223/jped.98 · Cited by 279
Price, R. N., Cassar, C., Brockman, A., Duraisingh, M., van Vugt, M., White, N. J., Nosten, F., & Krishna, S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2943 · Cited by 279 · cited 1×
“Resistance is associated with an increase in Pfmdr1 copy numbers [33–35].”
BackgroundSelf-citationGuyatt, H., & Snow, R. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.36 · Cited by 252 · cited 2×
“The newborn anthropometric results and neurological scores (Table 5) were very similar in the two groups and are consistent with having multiple malaria infections in pregnancy [18,43,45,46].”
BackgroundResultVugt, M. V., Wilairatana, P., Gemperli, B., Gathmann, I., Phaipun, L., Brockman, A., Luxemburger, C., White, N. J., Nosten, F., & Looareesuwan, S. (1999) · The American journal of tropical medicine and hygiene · doi:10.4269/ajtmh.1999.60.936 · Cited by 194
Self-citationBrockman, A., Price, R. N., van Vugt, M., Heppner, D. G., Walsh, D., Sookto, P., Wimonwattrawatee, T., Looareesuwan, S., White, N. J., & Nosten, F. (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90080-4 · Cited by 185 · cited 1×
“), but the exploratory analysis shows a clear superiority of AS7 over AL in this particular subgroup. There was no difference in efficacy between AL and AS7 in the treatment of primary or new infections. This difference between primary and recrudescent infections presumably reflects reduced class susceptibility of the…”
Self-citation
Cited by
Items 101–136 of 136
Improving the Role and Contribution of Pharmacokinetic Analyses in Antimalarial Drug Clinical Trials
Kay, K., Hodel, E. M., & Hastings, I. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02777-14 · Cited by 7
Updated pharmacokinetic considerations for the use of antimalarial drugs in pregnant women
Moore, B. R., & Davis, T. M. E. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1802425 · Cited by 7
Zongo, I. (2014) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · doi:10.17037/pubs.02026584 · Cited by 7
Saito, M., Wilaisrisak, P., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Koesukwiwat, U., Tärning, J., White, N. J., Nosten, F. H., & McGready, R. M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-24 · Cited by 5
“This is one explanation, and one that contributes to the lower lumefan trine efficacy in pregnancy (10, 22, 23).”
BackgroundSelf-citationNosten, F. H., Phillips‐Howard, P. A., & ter Kuile, F. O. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0480-2_5 · Cited by 12
“For pregnancy, however, this standard regimen is associated with lower plasma concentrations because of the increased volume of distribution and faster elimination, which will lead to treatment failures [82].”
Self-citationThe Role of Clinical Pharmacology in Chemotherapy of Multidrug‐Resistant Plasmodium falciparum
Karbwang, J., & Na‐Bangchang, K. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1589 · Cited by 6
Banda, C. G., Dzinjalamala, F. K., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., Lalloo, D. G., Khoo, S., & Mwapasa, V. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-18 · Cited by 4
Chemwor, G., Andagalu, B., Onyango, I., Opot, B., Okoth, R. O., Yedah, R. A., Juma, J. A., Mwakio, E. W., Wakoli, D. M., Amwoma, J. G., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.008 · Cited by 5
“The 28-day assessment of the efficacy of ACTs [ 39 , 40 ] showed that Kenyan parasites are still sensitive to ACTs [ 26 , 27 ].”
Ding, J., Hoglund, R. M., Tagbor, H. K., Tinto, H., Valéa, I., Mwapasa, V., Kalilani‐Phiri, L., Geertruyden, J. V., Nambozi, M., Mulenga, M., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13211 · Cited by 4
Therapy of vector-borne protozoan infections in nonendemic settings
Bottieau, E., Vekemans, M., & Gompel, A. V. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.32 · Cited by 4
Saito, M., Mansoor, R., Wiladphaingern, J., Paw, M. K., Pimanpanarak, M., Proux, S., Guerin, P. J., White, N. J., Nosten, F. H., & McGready, R. M. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz264 · Cited by 3
Self-citationEvaluation of malaria prevention strategies during pregnancy in Ndola, Zambia
Mulamba, M., & Mash, R. J. (2010) · African Journal of Primary Health Care & Family Medicine · doi:10.4102/phcfm.v2i1.159 · Cited by 3
Efficacy and safety of artemehter-lumefantrine in uncomplicated falciparum malaria in Liberia.
Rasheed, A., Khan, S. M., Awan, M. Y., Khurshid, U., & Ahmad, K. (2011) · PubMed · Cited by 3
Goel, R., Kumari, R., Singh, V., Pandey, R., Kumari, R., Srivastava, S., & Kumar, S. (2018) · Revista de Fomento Social · doi:10.16943/ptinsa/2018/49411 · Cited by 2
Treating malaria in pregnant women: a pressing problem
Gutman, J., & Kachur, S. P. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70216-4 · Cited by 2
Cohort Profile: the SMRU Refugee and Migrant Pregnancy Study in Western Thailand and Eastern Myanmar
McGready, R., J White, N., Nosten, F. H., & Collaborators, S. R. A. M. P. S. (2026) · Wellcome Open Research · doi:10.12688/wellcomeopenres.25582.2 · Cited by 2
Self-citationC linical Pharmacology of Anti-Infectives During Pregnancy
Best, B. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386007-1.00013-1 · Cited by 1
Saragih, S. W., Chalid, S. M. T., Malinta, U., & Wahid, I. (2017) · Indonesian Journal of Obstetrics and Gynecology · doi:10.32771/inajog.v5i3.537 · Cited by 1
Chukwu, L. C., Agbasi, P. U., Unekwe, P. C., & Oguwike, F. N. (2019) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2019.76005 · Cited by 1
“Also the duration is much less than that observed in some of the international studies assessing AL efficacy reported as 26 to 72 hours [8] [23] [24].”
ResultSpezielle Arzneimitteltherapie in der Schwangerschaft
(2012) · Elsevier eBooks · doi:10.1016/b978-3-437-21203-1.10002-0 · Cited by 1
“In der Schwangerschaft findet man geringere Plasmakonzentrationen und eine schnellere Elimination, die das Risiko von Therapieversagern erhöht (Tarning et al. 2009; McGready et al. 2008).”
Ainsworth, S. B. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198840787.003.0014 · Cited by 1
Population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin
Tan, B. S. (2009) · doi:10.17077/etd.vdkju8vf · Cited by 3
Hey, E. N. (2011) · Wiley eBooks · doi:10.1002/9781444329773.part2 · Cited by 1
Puerperal sepsis: a traveller's tale
Burke, K. A., & Gupta, M. (2013) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12250
“Misdiagnosis and treatment delay are the most commonly given reasons for malarial deaths in Europe (2) and there are currently no guidelines addressing the recognition of malaria in the acutely septic woman.”
BackgroundBandyopadhyay, D., & Singha, P. (2013) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v3i4.621
Control of Malaria During Pregnancy: Treatment of Uncomplicated Malaria and Complicated Malaria
D’Alessandro, U., & Hamel, M. J. (2015) · Springer eBooks · doi:10.1007/978-1-4614-8326-7_70
THÈSE POUR LE DIPLÔME D'ÉTAT DE
Médecine, D. E. (2007)
Carmona‐Fonseca, J., Agudelo-Garcia, O. M., & Arango, E. (2013)
Ainsworth, S. B. (2014) · Wiley eBooks · doi:10.1002/9781118819494.ch15
Clinical pharmacology of anti-infectives during pregnancy
Momper, J. D., & Best, B. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818902-3.00022-1
Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
Tärning, J., von Seidlein, L., Dondorp, A. M., White, N. J., & Maude, R. J. (2022) · BMC Research Notes · doi:10.1186/s13104-022-06212-y
Self-citationSaito, M., Carrara, V. I., Gilder, M. E., Min, A. M., Tun, N. W., Pimanpanarak, M., Viladpai-nguen, J., Paw, M. K., Haohankhunnatham, W., Konghahong, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14759838
Self-citationPatterson, C., Nabarro, L., Kumar, S., Nolder, D., & Chiodini, P. L. (2025) · Journal of Travel Medicine · doi:10.1093/jtm/taaf099 · Cited by 4
“Most recurrence is around D28–42, but late reported recurrence has been reported at D85 with quinine, 32 D98 with artesunate, D63 with artemether-lumefantrine, 33 and 121 days with mefloquine.”
Benz, U., Junnila, A., Müller, G. C., Schlagenhauf, P., Rothe, C., & Schwarz, M. (2026) · Malaria Journal · doi:10.1186/s12936-026-06181-8
Metadata
- Authors
- McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., Lindegardh, N., Singhasivanon, P., White, N. J., & Nosten, F.
- Affiliations
- Mahidol University (TH)
- Shoklo Malaria Research Unit (TH)
- Corresponding author
- McGready, Rose
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-23
- Volume
- 5
- Issue
- 12
- Pages
- e253
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2605900
- OpenAlex
- W2008309617
- Cited by
- 136
- References
- 45
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 13 · 2014: 14 · 2013: 9 · 2012: 13
- FWCI
- 12.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Greater South Information System
- Funders
- Wellcome Trust
- Mahidol University
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- artemether-lumefantrine, falciparum malaria, malaria in pregnancy, uncomplicated malaria, artemisinin-based combination therapy, cure rate, relapse, pharmacokinetics, lumefantrine, Karen women, birth outcomes, infant outcomes, safety and tolerability, northwestern Thailand
- MeSH terms
- Artesunate, Artemether, Lumefantrine, Adult, Animals, Antimalarials, Drug Therapy, Combination, Ethanolamines, Female, Fluorenes, Humans, Infant, Infant, Newborn, Plasmodium falciparum, Pregnancy, Thailand, Pregnancy Complications, Parasitic, Malaria, Falciparum, Parasitic Sensitivity Tests, Artemisinins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.